Physician profile
Heather J Jacobs
NPI 1235488446
$3,042.39
in general payments reported to CMS, 2019-2025
26 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $1,135 · 2023: $462 · 2024: $459 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.36 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $639.81 | 2021-2025 | Provenge |
| Astellas Pharma US INC | $313.97 | 2021-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $241.47 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $239.13 | 2022-2025 | |
| Genzyme Corporation | $174.51 | 2021-2022 | |
| Urovant Sciences INC | $170.97 | 2021-2022 | |
| Olympus America INC. | $162.53 | 2021 | |
| Janssen Biotech, INC. | $150.76 | 2023-2024 | Erleada |
| Teleflex LLC | $119.55 | 2022 | |
| Abbvie INC. | $111.49 | 2022-2023 | |
| Blue Earth Diagnostics | $104.47 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $98.31 | 2024-2025 | Lynparza, Welireg, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $95.21 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $88.29 | 2022-2024 | |
| Clarus Therapeutics INC. | $85.50 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $46.66 | 2021-2022 | |
| Allergan, INC. | $33.75 | 2021 | |
| Boston Scientific Corporation | $28.50 | 2021-2024 | Upsylon |
| Angiodynamics, INC. | $24.69 | 2023 | Nanoknife |
| Urogen Pharma, INC. | $18.71 | 2024 | |
| Endo USA, INC. | $18.24 | 2024 | Xiaflex |
| Endo Pharmaceuticals INC. | $17.52 | 2021 | |
| Telix Pharmaceuticals | $16.17 | 2022 | |
| Foundation Medicine, INC. | $14.96 | 2023 | Foundationone Liquid Cdx |
| Antares Pharma, INC. | $13.87 | 2021 | |
| Myovant Sciences INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.